missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human AGR3 (aa 38-64) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (89%), Rat (89%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-84177 (PA5-84177. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
AGR3 (Anterior Gradient 3) protein, also known as AG3 (hAG-3, HAG3 in human), or BCMP11, is a secreted cytoplasmic protein which is involved in metastasis induction and p53 tumour supressor inhibition. It may serve as molecular marker and potential therapeutic target for hormone-responsive breast tumours. Its Xenopus homolog is associated with anteroposterior fate determination during early development.
Specifications
Specifications
| Accession Number | Q8TD06 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 155465 |
| Name | Human AGR3 (aa 38-64) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AG3; AG-3; AGR3; anterior gradient 3; anterior gradient 3 homolog; anterior gradient 3, protein disulphide isomerase family member; anterior gradient homolog 3; anterior gradient protein 3; anterior gradient protein 3 homolog; BCMP11; Breast cancer membrane protein 11; E030025L21Rik; Gm888; H PDIA18; HAG3; hAG-3; PDIA18; Protein disulfide isomerase family A, member 18; RGD1565406; UNQ642/PRO1272 |
| Common Name | AGR3 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction